Aspergillosis in systemic lupus erythematosus

被引:33
作者
Katz, A [1 ]
Ehrenfeld, M [1 ]
Livneh, A [1 ]
Bank, I [1 ]
Gur, H [1 ]
Pauzner, R [1 ]
Many, A [1 ]
Langevitz, P [1 ]
机构
[1] TEL AVIV UNIV, SACKLER FAC MED, IL-69978 TEL AVIV, ISRAEL
关键词
systemic lupus erythematosus; infection; aspergillosis; corticosteroids;
D O I
10.1016/S0049-0172(96)80014-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Infection is the major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Although various fungi account for a substantial number of these lethal infections, aspergillosis, an important opportunistic infection in immunosuppressed patients, is described rarely. Only 23 cases have been reported in the English-language medical literature. Risk factors for acquiring aspergillosis in these patients were high grade disease activity, granulocytopenia, use of steroids and other immunosuppressive treatment and presence of bacterial infection. The diagnosis in most patients was delayed and they died. Here, we describe three SLE patients with invasive aspergillosis. Features of our patients' diseases were similar to those reported previously. Aspergillosis appeared while they had active SLE treated with high dose corticosteroids. In 2 patients the fungal infection was systemic and diagnosed post mortem. Both were leukopenic and had concurrent bacterial infection and one received amphotericin B prior to death. In the third, the infection was localized to a transplanted kidney and was cured by nephrectomy. Aspergillosis should be suspected in patients with active SLE, who are immunocompromised and sustain concomitant bacterial infections. The currently poor prognosis may be improved with more aggressive diagnostic investigation and treatment. Copyright (C) 1996 by W.B. Saunders Company.
引用
收藏
页码:635 / 640
页数:6
相关论文
共 37 条
[1]  
Armstrong D, 1989, REV INFECT DIS S7, V11, ps1591, DOI [10.1093/clinids/11.Supplement_7.S1591, 10.1093/clinids/11.supplement_7.s1591]
[2]  
Bennett J. E., 1990, Principles and practice of infectious diseases., P1958
[3]   ASPERGILLOSIS [J].
BODEY, GP ;
VARTIVARIAN, S .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (05) :413-437
[4]   COURSE OF SYSTEMIC LUPUS ERYTHEMATOSUS [J].
CARPENTER, RR ;
STURGILL, BC .
JOURNAL OF CHRONIC DISEASES, 1966, 19 (02) :117-+
[5]   CURE OF ASPERGILLUS-USTUS ENDOCARDITIS ON A PROSTHETIC VALVE [J].
CARRIZOSA, J ;
LEVISON, ME ;
LAWRENCE, T ;
KAYE, D .
ARCHIVES OF INTERNAL MEDICINE, 1974, 133 (03) :486-490
[6]  
COHEN J, 1982, Q J MED, V51, P1
[7]  
CORTET B, 1994, J RHEUMATOL, V21, P1287
[8]   TREATMENT OF INVASIVE ASPERGILLOSIS WITH ITRACONAZOLE [J].
DENNING, DW ;
TUCKER, RM ;
HANSON, LH ;
STEVENS, DA .
AMERICAN JOURNAL OF MEDICINE, 1989, 86 (06) :791-800
[9]  
DENNING DW, 1990, REV INFECT DIS, V12, P1147
[10]  
DUFFY KNW, 1991, J RHEUMATOL, V18, P1180